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Head and neck squamous cell carcinoma (HNSCC) is a relevant medical issue since it is the sixth 
most common cancer globally and its incidence is increasing. It is is generally associated with a 
history of alcohol and tobacco consumption or abuse, and remarkable an etiopathogenetic 
correlation between tumor and Human Papilloma Virus (HPV). Surgery, radiotherapy and 
chemotherapy in various combinations are used in the treatment of head and neck cancers, 
depending on the TNM stage. Chemo-radiotherapy mechanisms of action against tumors 
considers the activation of anti-cancer immune response as a key event, since radiations act as 
a sort of "in situ vaccination”. Radiotherapy promotes the inflammation and subsequent 
activation of adoptive immune responses against tumor-associated antigens (TAA) released or 
expressed by the tumor.  The peripheral immune response of 20 patients suffering for HNSCC 
was monitored using multiparametric flow cytometry in order to define the qualitative and 
quantitative characteristics of their immunological T cell response (CD4+ and CD8+ T 
lymphocytes maturation stage; cytokine production; regulatory commitment; expression of 
markers of exhaustion/IRs), before and after these subjects underwent chemo-radiotherapy 
treatment. The immunological monitoring data collected suggest an activatory effect on the 
immune system after therapy possibly due to the huge amount of cell death products acting as 
danger signals raised by chemotherapy-Rt combination and by the subsequent stimulation of 
cancer specific immune responses induced by antigen spreading. Peripheral blood samples of 
patients examined showed that therapy mainly induced a decrease of the CD3+ total T cell; the 
CD4+ T cells switched from the naïve to the late maturation stages cell subset expressing the 
PD-1 molecule, associated with an increase in secretion of Granzyme; on the CD8+ T cell 
compartment the therapy induced pro-maturation effects pushing them toward acquisition of 
full effector functions, suggested by the expansion of the CD8+CD28- T cell subset and by the 
decrease of the early maturation stages associated with the increase of Terminal Effector 
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1.1 Head and Neck Squamous Cell Carcinoma (HNSCC) 
 
Head and neck squamous cell carcinoma (HNSCC) is a relevant medical issue since it is the sixth 
most common cancer globally and its incidence is increasing. Malignant tumors of the head and 
neck represent about 3% of all malignant tumors in Italy; approximately 12,000 new cases are 
diagnosed each year. The incidence rate is 16 cases per 100,000 Italians per year, while in 
Europe it is 18 per 100,000. Almost 90% of the malignant tumors of the head and neck are 
represented by squamous cell carcinomas which can have an extremely variable biological 
behavior in the different locations of the cervico-cephalic area [1]. 
Tumors of the oropharynx (OPSCC) are relatively frequent in the head and neck area. Based on 
existing cancer registries, the incidence in Italy in the period 1995-2002 was 2.58 cases per 
100,000 inhabitants. Men are affected more than women (M: F = 6: 1) especially between the 
ages of 50 and 70. In recent decades, the incidence of tumors related to the infection of the 
Papilloma virus (Human Papilloma Virus HPV) has significantly increased. [2]. 
Head and neck squamous cell carcinoma (HNSCC) is generally associated with a history of 
alcohol and tobacco consumption or abuse, which are predisposing factors also for other 
tumors of the upper respiratory tract, thus favoring a not negligible incidence of multiple 
synchronous or metachronous tumors [3]. 
The etiopathogenetic correlation between HPV infection and the appearance of squamous cell 
carcinomas of the oropharynx (especially of the palatine and lingual tonsil) with a relatively 
favorable prognosis is now well established. Patients with HPV + tumors are generally younger 
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than those with HPV-negative, less comorbid, socially active tumors, so preserving quality of 
life after treatment becomes a priority [4]. 
Surgery, radiotherapy and chemotherapy in various combinations are used in the treatment of 
head and neck cancers, depending on the TNM stage. 
The early stage ones (T1-2, N0-1) can be treated with surgery - more specifically trans-oral or 
open resection, with or without neck dissection or with radical radiotherapy. 
Relating to locally advanced stage cancers  (T3-4, N0-1 or any T, N2-3),  radiotherapy associated 
with cisplatin-based chemotherapy is considered the standard, as chemo-radiotherapy 
compared to radiotherapy alone has shown a significant improvement in overall survival, 
locoregional control and disease free survival [5-6]. 
 
 
1.2 Immune response to cancer 
  
Cancer result from uncontrolled proliferation and spread in the body of clones of transformed 
cells, characterized by the accumulation of a variable number of genetic alterations and the loss 
of normal cellular regulatory processes.  
The immune system takes advantages of at least three functions to try to prevent the 
development of tumors: a) protection of the host from viral infections and therefore from virus-
induced tumors; b) prevention of the establishment of an inflammatory microenvironment 
favoring carcinogenesis by eliminating pathogens and therefore rapidly resolving 
inflammatory state; c) elimination of transformed cancer cells by specific immune cells. [7-8-9] 
Recent studies showed how the immune system recognizes tumor cells through tumor-
associated antigens (TAA), a large category  that includes: differentiation antigens (such as 
melanocyte differentiation antigens), mutational antigens (such as p53), overexpressed cellular 
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antigens (such as HER-2), viral antigens (such as human papillomavirus proteins), and 
cancer/testis (CT) antigens that are expressed in germ cells of testis and ovary but silent in 
normal somatic cells (such as MAGE and NYESO-1).  
In recent years it has become evident that the immune system plays a dual role in relation to 
cancer:  on one side,  immune system has the ability to protect the host against tumor formation 
(immunosurveillance), on the other side can enhance tumor-promoting actions and modulates 
the immunogenicity of cancer cells (editing). This complex relationship between immune 
system and tumor give rise over time to a consolidated hypothesis that takes the name of 
“cancer immunoediting”. 
The cancer immunoediting process can be distinguished in three phases: 1) Elimination, 2) 
Equilibrium, 3) Escape. (FIG.1) 
 
 
FIG.1. Cancer immunoediting process A dynamic relationship is established between the immune cells and the tumor, called 
immunoediting, which reflects the dual role of the immune system in promoting the protection of the host from the tumor and 
in favoring tumor escape versus immune destruction. The immunoediting process is divided into three phases: 1) elimination 
of tumor cells thanks to immunosurveillance; 2) phase of equilibrium in which the tumor cells are controlled but not eliminated; 
3) escape phase in which the modification of cancer cells involves loss of the immune response and favors the progression of 





During the elimination phase, the innate and adaptive immune systems work together to detect 
the presence of a developing tumor and destroy it before it becomes clinically apparent.  Many 
molecules, that act as “Danger signals”,  are induced early during tumor development: Type I 
IFNs activate dendritic cells and promote induction of adaptive anti-tumor immune responses; 
damage-associated molecular pattern molecules (DAMPs) released directly from dying tumor 
cells [such as high mobility group box 1 (HMGB1)] or from damaged tissues (such as 
hyaluronan fragments), as well as stress ligands, that are frequently expressed on the surface 
of tumor cells, activate receptors on innate immune cells, which release pro-inflammatory and 
immunomodulatory cytokines, which in turn establish a microenvironment that facilitates the 
development of a tumor-specific adaptive immune response that requires the additional 
expression of tumor antigens capable to promote the  expansion of effector CD4+ and CD8+ T 
cells. 
In the equilibrium phase, the host's immune system and the tumor cells, that survive the 
elimination phase,  enter into a dynamic equilibrium, in which the lymphocytes and IFN-γ exert 
a powerful selection pressure on the tumor cells that is sufficient to contain, but not completely 
extinguish the tumor containing many genetically unstable and mutant tumor cells. This is the 
longest phase of the three processes of cancer immunoediting and can last for many years. The 
end of equilibrium process hesitates into a new population of tumor clones with reduced 
immunogenicity, derived from a heterogeneous parental population by the modeling forces of 
the immune system. 
Finally, in the escape phase, tumor cells acquire the ability to circumvent immune recognition 
and destruction. Progression from equilibrium to the escape phase can occur because the tumor 
cell population changes in response to the immune system’s editing functions and/or because 
the host immune system changes in response to increased cancer-induced immunosuppression 
or immune system deterioration. Tumor cell escape can occur through many different 
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mechanisms: a)- loss of tumor antigen expression, which involves MHC class I molecules; b) 
production of immunosuppressive cytokines (as IL-10, TGF-β); c)-recruitment of regulatory T 
cells (Treg)  and myeloid-derived suppressor cells (MDSCs). [10-11-12] 
The importance of T lymphocytes in all their forms in the cancer immunoediting process, 
especially as infiltrating CD8 + T cells, has been demonstrated in many preclinical mouse 
models and in human tumors. In recent years, the study of the T populations of both the 
peripheral district and the tumor site by the different technological platforms has assumed 





1.3 T lymphocytes  
T lymphocytes derive, just like B lymphocytes, from the multipotent haematopoietic progenitor 
which migrates from the bone marrow to the thymus  (hence the name thymus-dependent 
lymphocytes) where it undergoes a complex maturation process. Through a sophisticated 
mechanism of elimination of T cells potentially autoreactive or unable to recognize the antigens 
presented by MHC-molecules in the thymic stroma which implies the positive and negative 
selections,  the final result consists of the generation of a mature conventional CD4+ and CD8+ 
T cell repertoire that is both MHC-restricted and tolerant towards autologous peptides. The 
hallmark of a T cell is expression of an antigen-recognizing T cell receptor (TCR),  composed of:  
an α - and β -chain (TCR α: β) expressed by 95% of peripheral CD3+ T cells or and a γ- and δ –





1.4 T effector cells and Maturation 
The mature CD3+T cell population appears extremely heterogeneous and can be divided into 
distinct subsets based on their phenotype. The association between distinct subsets and the 
expression of surface receptors and intracellular molecules implies that these T cell subsets 
exhibit differential requirements for stimulation and survival, homing potential (e.g., to 
lymphoid organs or to peripheral tissues) and some (immediate) effector functions. 
Human naïve and memory T cells can be identified by the reciprocal expression of the most-
commonly used markers: CD45RA (or the isophorm CD45RO) and CCR7, a chemokine receptor, 
which allows them to be recycled in the areas reserved for T lymphocytes within peripheral 




FIG.2. Diagram of the maturation stages of T lymphocytes based on the expression of CD45RA and CCR7. 
 
Staining of peripheral blood T cells with antibodies to CD45RA and CCR7 revealed four subsets 
of CD4+ cells ad well as CD8+ cells (Fig.2):  
- T Naïve (CD45RA+CCR7+), that have not previously contacted their relevant antigen. Naïve T 
cells are programmed to recirculate from blood into peripheral lymphoid tissues and then 
back to blood; 
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- Central memory T cells or TCM (CD45RA-CCR7+) are very sensitive to the activation of their 
receptors, rapidly expressing the CD40 ligand in response; however, they are slower than 
other subsets in acquiring effector functions, such as the production of cytokines;  
- T Effector Memory or TEM (CD45RA- CCR7-) even if they lack the CCR7 chemokine receptor, 
this cells subset express high levels of β1 and β2 integrins, are therefore able to rapidly enter 
inflamed tissues, and have the ability to rapidly assume effector function and thus secrete 
large amounts of IFN-γ, IL-4 and IL-5 upon stimulation;  
- Terminal Effector Memory or TEMRA (CD45RA+ CCR7-) which consists of those effector cells 
which are terminally differentiated and which, however, return to express the CD45RA a 
marker that is typically found on T Naïve.  [15-16- 17] 
Regardless of each maturation stage, the recognition of the antigen and the consequent 
response to it, is subjected to a series of primary and secondary signals, so that is a tightly 
controlled process at every step of a mature T cell response. 
Primary signal for conventional T cells is mediated through TCR engagement. Conventional T 
cells through their TCR recognize small antigenic peptides presented in the groove of the self 
major histocompatibility complex (MHC) by antigen presenting cells  (APC).  As a result of this 
recognition, TCR complexes aggregate on T cell surfaces to form stable contacts resulting in the 
formation of immunological synapses on APC. Early intracellular signaling, following TCR 
engagement, involves the activation of protein tyrosine kinases (PTK), leading to the 
phosphorylation of CD3-localized immunoreceptor tyrosine-based activation motifs (ITAMs). 
Subsequently, the PTK ZAP-70 is recruited, resulting in a series of phosphorylation events. 
After recognition of peptide–MHC complexes on APCs, secondary signal receptors colocalize 
with TCR molecules at the immunological synapse, where they promote or inhibit T cell 
activation and function. In fact, the balance between co-stimulatory receptors and inhibitory 
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receptors (iRs) allows to control the T cell response at every step, from T cell priming, T cell 
expansion, and contraction, to the various functions of memory T cells. [18] 
 
 
Fig.3.Cell Surface Signaling Molecules in the Control of Immune Responses [18] 
 
Expression of co-stimulatory and inhibitory molecules on the surface of T cells (Fig.3) is 
induced following activation and that changes in the cell surface expression of many molecules 
occur in overlapping fashion as T cells proliferate and differentiate. [19]  
Co-stimulatory receptors, such as CD28 and CD27 molecules  are involved respectively in the 
regulation of T-cell activation and in the generation of antigen-primed cells.  Both CD28 and 
CD27 markers are  constitutively expressed on the cell surface of naive CD4+ and CD8+ T cells 
and in particular CD28 provides an essential co-stimulatory signal for T cell growth and survival 
upon ligation by B7-1 and B7-2 molecules on APCs. The expression of CD28 and CD27 markers 
are  modulated in the later stages of maturation and activation (TEM and TEMRA); CD28 has a role 
in memory T cell survival, and with CD27 promotes memory CD4+ and CD8+ T cell responses. 
During the peak of T cell activation, the expression of co-stimulatory receptors is replaced by 




Co-inhibitory or inhibitory receptors (iRs) are molecules that negatively interfere with T cell 
activation. Their primary role regards the regulation of immune homeostasis and preservation 
of healthy tissue from autoimmunity. They function at several levels: (1) through competition 
with co-stimulatory receptors for binding to shared ligands or interference in the formation of 
microclusters and lipid rafts; (2) by interfering with downstream signals from co-activatory 




Fig.4 Major inhibitory receptor mechanisms of action. Mechanism#1: Inhibitory receptors prevent T cells (or B cells) from 
receiving complete activation signals by sequestering the ligands for costimulatory receptors. Mechanism #2: Inhibitory 
sequence motifs, such as ITIMs or ITSMs, on the cytoplasmic tail of inhibitory receptors are phosphorylated upon cellular 
activation. #3: Inhibitory receptors were recently demonstrated to upregulate genes that inhibit immune cell function; 
however, the pathways leading to this gene upregulation are not known. [22] 
 
Two of the probably most well-studied T cells related iRs are Programed Cell Death 1 (PDCD1, 
also called PD-1) and Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA-4). CTLA-4 and PD-




CTLA-4 is up-regulated following T cell activation and is involved in later stages of T cell 
priming and systemic activation of T cell responses. CTLA-4 counteracts the positive signal 
mediated by CD28 by competing for the same ligands (CD80/86) with higher affinity.      CTLA-
4 is up-regulated upon activation on naïve T cells and constitutively expressed on regulatory T 
cells. Paradoxically, although CTLA-4 decreases effector functions of CD4+ and CD8+ T cells, it 
increases the suppressive capacity of Tregs. Thus, CTLA-4 dampens T cell activation, decreases 
the efficacy of antigen presenting cells to activate T cells and augments Treg mediated immune 
suppression. Whereas CTLA-4 predominantly regulates initial T cell activation, the inhibitory 
receptor programmed cell death 1 (PD-1) dampens effector T cell functions, which are which 
are typically carried out by T cells in an advanced state of maturation. In fact, Transient PD-1 
cell surface expression is initiated upon T cell activation and plays a role at later stages of the 
immune responses when T cells are already activated. [19] 
Beside iRs activity, other pathways work in order to prevent inappropriate activation of the 
immune system. One of these is the co-inhibitory pathways associated with purinergic signaling 
with the focus on CD39 and CD73, extracellular nucleotide scavenging, and adenosine 
generation. 
Extracellular release of purine nucleotides, such as adenosine triphosphate (ATP) and 
adenosine diphosphate (ADP), plays a fundamental role in regulating inflammation and tissue 
homeostasis through the activation of purinergic P2 receptors. The conversion of ATP/ADP to 
adenosine is the consequence of the action of cell-surface ectonucleotidases CD39 and CD73. 
CD39, or ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1), hydrolyses 
extracellular ATP and ADP into adenosine monophosphate (AMP), which  is then processed into 
the anti-inflammatory adenosine, essentially by the ecto-50-nucleotidase CD73. Upon binding 
to A2A receptors on T cells, adenosine induces the accumulation of intracellular cyclic AMP, 
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thereby preventing TCR-induced CD25 upregulation and inhibiting effector T-lymphocyte 
proliferation and inflammatory cytokine secretion. [23-24-25] 
 
 
Fig.5 CD39 and CD73 shape the “purinergic halo” surrounding immune cells. The occurrence of pathological events, such 
as inflammation, promotes a massive accumulation of ATP, which serves as a key “danger” signal, triggering a series of 















1.5 T cells exhaustion 
T cell exhaustion occurs as the result of persistent antigen stimulation and consequent 
inflammation state induced during chronic infections or cancer.   
Exhaustion is intimately linked to concurrent analyses of functional effector and memory T cells 
and represent a distinct and dysfunctional state of CD8+ and CD4+ T cell differentiation. 
Exhausted T cells are thought to develop during the progression from effector T cells to mem-
ory T cells, so it has been proposed that exhaustion of T cells may prevent the terminal 




Fig.6 Levels of iR may peak at the effector phase, and may further modulate differently during acute versus chronic 
immune responses. [20] 
 
During exhaustion, T cells progress through stages of dysfunction in a hierarchical manner, 
losing effector functions and other properties, becoming gradually silenced due to continuous 
T cell receptor (TCR) stimulation, resulting in impaired effector cytokine production (e.g., IFNg, 
TNFa, or IL-2), and impaired ex vivo cytotoxicity compared with effector T cells. [26-27-28]  
Hallmarks of exhaustion mechanisms are: a) the elevated expression of multiple co-inhibitory 
receptors (PD-1, TIM-3, CTLA-4, BTLA, CD160, LAG-3) which in turn highly correlates with the 
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degree of unresponsiveness, in particular, the axis of PD-1 and its ligand seems to be a major 
inhibitory receptor pathway involved; b) the role of immunoregulatory cytokines (such as IL-
10 and  TGF-β), and immunoregulatory cell types (such as Treg cells and other cells).  Hence,  
immunoregulation is centrally involved in T cell exhaustion. [26]  
 
 
1.6 T regulatory cells 
 
Regulatory T (Treg) cells are essential for maintaining peripheral tolerance, preventing 
autoimmune diseases and limiting chronic inflammatory diseases. However, they also limit 
beneficial responses for example limiting anti-tumour immunity. [29] 
The mechanisms by which Treg lymphocytes regulate the immune response can be 
summarized in four fundamental "modes of action" (Fig.7):  
1. suppression by inhibitory cytokines (IL-10, TGFβ, IL-35);  
2. suppression by cytolysis;  
3. suppression by metabolic interference as: deprivation of IL-2 which binds to high affinity IL-
2 receptor (CD25) on Treg cells resulting in the apoptosis of effector T lymphocytes; and 
generation of immunosuppressive adenosine through degradation of ATP by the CD39 and 
CD73 ectonucleotidases; [30-31]  
4. suppression by modulation of function or maturation of antigen presenting cells, through the 
IRs: LAG3 (which suppresses the maturation of dendritic cells) and CTLA-4 (which induces 








Fig.7 Operative modalities of the immunomodulatory function of Tregs: production of IL-10, TGFβ and Il-35 (top), direct 
elimination of T eff (right), metabolic destruction of T eff by means of CD25 (by deprivation of IL-2 ), CD39 and CD73 (below). 
 
 
The action of Treg lymphocytes is important in preventing excessive inflammatory reactions 
when the antigen has been eradicated, thus preventing the activated lymphocytes from leading 
to tissue damage. On the other hand, in the context of neoplastic pathologies, an imbalance of 
the immune response in a suppressive sense would seem to give the tumor an advantage and 
therefore the possibility of prevailing (escape) over the cytotoxic immune response [32-33]  
Several subsets of T cells with regulatory activities have been described.  
Among CD4+ T lymphocyte subpopulations with immunomodulatory activity, it is possible to 
distinguish CD4+ CD25high Treg cells, so the cardinal feature of Treg cells subset is the 
constitutively expression high-affinity IL-2 receptor (CD25).  [34].  
Treg cells can be distinguished from recently activated T lymphocytes, that represents the 30% 
human peripheral blood and express low levels of CD25, by the expression of the nuclear 
transcription factor Forkhead box P3 (Foxp3) and the low intensity expression of the IL-7 





Several  studies  have shown remarkable plasticity and heterogeneity of  CD4+Treg populations 
and according on their site of differentiation  CD4+Tregs are classified in:  thymus-derived 
natural Tregs (nTregs),  Foxp3+, that express marker of activation (HLA-DR)  and functional 
markers (GITR, CTLA-4, CD39); and peripherally induced Tregs (pTregs), also FOXP3+,  
resulting from the conversion of naïve CD4+T cells in presence of interleukin-10 (IL-10) and/or 
transforming growth factor-β (TGF-β), as Th3 (first identified for  their role in oral tolerance 
through the secretion of TGF-β ) and Tr1, characterized on the basis of their role in preventing 
autoimmune colitis and their ability to secrete large amounts of IL-10. pTregs, generated in 
chronically inflamed tissues, are implicated in the induction of oral and gut tolerance.  Moreover 
the In vitro generation of Tregs in the presence of IL-2 and TGF-β polarizing conditions leads 
to the development of iTregs FOXP3+ (Fig.8) [36] 
 
 
Fig.8 Regulatory T cell populations. The image shows the Treg cell populations. Natural Tregs are produced in the thymus 
together with naïve T which, subsequently, can differentiate in the periphery into different subsets of T cells: Th1, Th2, Th17, 
induced Treg, all having distinct immunological roles. The differentiation process is controlled by several cytokines. Th1 cells 
are induced by IL-2 and IFNγ; the Th2s differ thanks to IL-4; the Th17s thanks to IL-1β, IL-6, IL-23 and TGF-β. Each separate 
subset of T cells can be identified by specific transcription factors: T-bet (Th1), GATA3 (Th2), RORγt (Th17), FOXP3 (Treg) and 
has its own immunological role: Th1 secrete IFNγ, controlling the immunity to foreign pathogens. Th2s produce various 
cytokines including: IL-4, IL-5, IL-13, IL-10, which are mainly involved in promoting humoral immunity, protecting against 
infections. Th17s mainly produce IL-17 and IL-22. Despite the apparent terminal differentiation of all these cells, they 
absolutely cannot be considered definitive stages of cellular life. The possibility of changing phenotype during the exhaustion 







Furthermore, recent papers described a dissection of  CD4+ CD25high FOXP3+ CD127dim/neg  Treg 
cells in humans into three subpopulations based on expression levels of FOXP3 (or CD25) and 
the cell surface molecule CD45RA (Fig.9): (i) FOXP3lowCD45RA+CD25low cells, designated as 
naive or resting Treg cells; (ii) FOXP3highCD45RA–CD25high cells, designated as effector or 
activated Treg cells, which are terminally differentiated upon antigen stimulation and exert 
their highly suppressive action expressing IRs including CTLA-4 and PD-1; and (iii) 
FOXP3lowCD45RA–CD25low non-Treg cells, which do not possess suppressive activity but can 
secrete pro-inflammatory cytokines. [32] 
This classification delineates developmental stages of Tregs and assessing their adaptive 
processes in physiological and pathological immune responses.  
 
 
Fig.9 Functional classification of human FOXP3+CD4+ T-cell subpopulations. Human FOXP3+ T cells are composed of 
heterogeneous subpopulations containing suppressive Treg cells (naïve and effector Treg cells) and activated non-Treg cells 
without suppression function. These subpopulations are designated as Fraction (Fr.) I, II, and III for naive Treg (nTreg), effector 
Treg (eTreg), and non-Treg cells, respectively. CD25 surface marker can be used in the place of FOXP3 because of their 







The regulatory T cell family also includes subsets belonging to the CD8+ T cell compartment.  It 
is interesting to note that, both in humans and in the animal model, different CD8+ Treg 
subtypes have been identified that differ according to the molecular phenotype and the 
mechanism of action.  Similarly to CD4+Tregs, thymus-derived  or natural CD8+Treg 
populations have been described that are activated by direct antigen recognition and express 
the transcription factor FoxP3 and CD25: moreover they act generally through cell-to-cell 
contact. 
Several types of peripherally induced CD8+Tregs have been described in humans  induced after 
one time or several rounds of stimulation after loss of CD28 expression. The evidences suggest 
that the adaptive CD8+Tregs can originate from cells initially not regulatory and acquiring 
suppressor activity after repeated antigen stimulation in presence of polarizing milieu. [36-37] 
In particular, CD8+CD28- non-antigen-specific Treg cells appear to play a relevant role in tumor 
microenvironment, as well as in the pathogenesis of different autoimmune and infectious 
diseases [38]. These CD8+ Treg lymphocytes show a very low frequency (≤0.1% of peripheral 
CD3+T lymphocytes) in healthy donors, but they can be generated from circulating CD8+ 
lymphocytes following in vitro conditioning with IL-2 and IL-10. Whereas, in oncologic patient, 
active immunosuppressive CD8+Treg cells  represent a large component of tumor- infiltrating 
T cells and their frequency in peripheral blood resulted significantly higher than that measured 
in the peripheral blood of healthy subjects  .  
The loss of co-stimulatory CD28 receptor suggests that they fall within the so-called 
“peripherally induced” CD8+ Treg [39]. The so far detailed phenotype of the regulatory 
subpopulation is CD8+CD28-CD127lowCD39+ and takes into account maturation state and 
functionality of this subset. Similarly to CD4+ CD25high FOXP3+ CD127dim/neg  Treg cells, the 
maturation of circulating CD8+CD28- cells in regulatory cells is accompanied by the down-
modulation of CD127. Several evidences showed that: 1) they are able to inhibit both cell 
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proliferation and cytotoxicity of effector T cells through the secretion of cytokines, mainly IL-
10; 2) they do not require direct contact with the target cell to exert suppressive activity [40]; 
and 3) they  act through regulatory mechanism that includes the activity of CD39. [31,41]. 
In conclusion, several T cell populations endowed with potent immunomodulatory capacities 
have been identified in both the CD4+ and CD8+ compartments. The fundamental difference 
between CD4 +and CD8+ T cells in terms of antigen recognition suggests non-redundant, and 
perhaps complementary, functions of CD4+ and CD8+ T regulatory cells.  This emphasizes the 
importance and necessity of continuous research on both subpopulations of regulatory T cells 
so as to decipher their complex physiological relevance and possible synergy in homeostasis 
and in clinical settings. 
 
 
1.7 Current therapeutic approaches for HNSCC 
The current therapeutic approaches for HNSCC include radical surgery and radiotherapy (RT), 
and for advanced stages either radical surgery followed by chemo/radiotherapy (CRT), primary 
chemo radiotherapy, combination of chemo/radiotherapy with Cetuximab (an anti-epidermal 
growth factor-receptor), or pembrolizumab (ananti-PD1 monoclonal antibody) for 
recurrent/progressive disease [42-43-44-45] 
To date, platinum-based chemotherapy remains first line systemic therapy both in the curative 
and recurrent and/or metastatic (R/M) setting. The abnormal activation of the epidermal 
growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, is a 
key feature of epithelial cancers, including head and neck cancer. In general, its presence is 




The approval of the epidermal growth factor-receptor (EGFR) antagonist cetuximab introduced 
the first targeted therapy in HNSCC showing increased locoregional control when compared to 
RT alone and improved outcome when combined with chemotherapy. Interestingly, the 
immune system appears to affect treatment response in the context of RT/CRT. Accumulating 
data regarding the interplay between tumor/microenvironment and the immune contexture as 
well as mechanisms underlying immune-checkpoint pathway regulation, suggest that targeted 
therapies can promote anti-tumor immunity and mediate durable cancer regression.  
Radiotherapy increases the expression of EGFR in cancer cells, so the combination with 
Cetuximab (Erbitux, ImClone Systems), an IgG1 monoclonal antibody against the ligand binding 
domain of EGFR, stimulates antibody-dependent cell-mediated cytotoxicity. [46] 
Despite these options available for treatment, the mortality rates for patients with HNSCC are 
still very high (mainly in advanced/metastatic or recurrent disease). 
 
1.8 Radiotherapy 
An updated view on radiotherapy (RT) mechanisms of action against tumors considers the 
activation of anti-cancer immune response as a key event. RT is considered a local therapy, that 
acts by direct energy deposition within the tumor bed leading to DNA lesions and extensive cell 
death.   
Local effects enhance a phenomenon also known as “in situ vaccination”. The radiation 
“unmasks” the tumor through Immunogenic Cell Death, in other words eliciting antigen release 
from dying cancer cell. The availability of tumor antigen and neoantigen can thereby reverse 
the evasion mechanism from the immune response, making cancer accessible to both the innate 







Fig.10 Pro-immunogenic and immunosuppressive properties of radiation. 
 
Different and multiple mechanisms are involved in Immunogenic Cell Death induced by 
Radioterapy. 
Irradiated cells release danger-associated molecular patterns (DAMPs), that act as extracellular 
signaling, such as: 
-high mobility group box1 (HMGB1), heat-shock proteins, uric acid, activate toll-like receptor 
signaling, which leads to dendritic cell maturation and priming of cytotoxic T lymphocytes 
(CTLs);  
-adenosine triphosphate (ATP) acts through cell surface purinergic receptors to attract 




exposure of calreticulin on the tumor cell surface. Calreticulin acts as a phagocytotic signal for 
dendritic cells and macrophages.  
Radiation also induces several phenotypic changes in tumor cells to facilitate immune 
detection. The recurrent expression of several cell surface death receptors enhances 
susceptibility of tumor cell death in the presence of immune cells expressing the corresponding 
ligands: 
 -upregulation of FAS receptor by radiation can be engaged by its specific ligand FAS-L to trigger 
extrinsic caspase-dependent apoptosis; 
 -radiation-induced death receptor 5 (DR5), that sensitizes cancer cells to apoptosis via binding 
of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL); 
 - expression of co-stimulatory molecule CD80 and stress-induced NKG2D ligand are promoted 
by radiation to facilitate tumor cell clearance by T cells and Natural Killer (NK) cells. 
RT modulates the tumor vascular endothelium, inducing cell adhesion molecules that further 
promote recruitment of anti-tumor immune cells: 
 -increases the expression of E-selectin and ICAM1 in human endothelial cells thus modifying 
immune-cell permeability of the tumor vasculature,  
-facilitates the recruitment of effector T-cells to tumors through the induction of chemokines. 
In particular, the recruitment of CD4+ and CD8+ T-cells is led by the induction of CXCL16, CXCL9 
and CXCL10 chemokine. 
Radiation also upregulates the release of pro-inflammatory cytokines, including interleukin-1 
beta (IL-1 β), tumor necrosis factor alpha (TNF-α), and type I and type II interferons (IFNs). 
Irradiated tumor cells upregulate MHC-I and facilitate tumor antigen uptake by DCs, in order to 





With the induction of an Immunogenic Cell Death, that includes all these phenomena, 
radiotherapy engages both the innate and adaptive arms of the immune system, coupling the 
release of antigens with immune adjuvant-like effects, with the potential to convert the 




Fig.11 Cells undergoing immunogenic cell death in response to stress such as radiotherapy. Dying cells emit a panel of 
immunostimulatory damage-associated molecular patterns (DAMPs) and cytokines that support the recruitment, 
phagocytic activity and maturation of antigen-presenting cells (APCs). APC migrate to lymph nodes and prime a cytotoxic T 
lymphocyte (CTL)-dependent immune response and induce an immunological memory in periphery. [53] 
 
It has also been recognized that local RT can act outside the directly irradiated site as well. RT 
systemic responses were observed towards tumor regression at sites distant from the 
irradiated region and is commonly known as the “abscopal effect”. RT effects synergize with 
other antitumor treatment modalities (chemotherapy, immunotherapy), and might influence 
long-term treatment outcome both in terms of local tumor control and development of distant 
metastases, initiating inflammatory and immune reactions outside the directly irradiated 
tissues. [52]  
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Despite a lot of data in literature supporting the systemic effect of radiotherapy, whose main 
function seems to be to act as an in-situ vaccination, little is known about the modulation of 
peripheral blood T cells population in response to this kind of therapy. 
In Non-small Cell Lung cancer RT increased the frequency of total T cells, especially the 
proportion of CD8+ T cells, but decreased the frequency of inhibitory Tregs. Peripheral CD8+ 
and CD4+ T cells were mainly activated, expressing high levels of TNF-α, IFN-γ, granzyme B and 
IL-2. Also, PD-1 and Ki67 expression were found increased indicative of an active T-cell 
functionality. [56-57] 
Almost the same effects were detected on Esophageal Cancer and Cervical Cancer patients 
accompanied by unfavorable CD8+ cells/Treg ratio upon radiation treatment. [58-59] 
It has also been reported that in peripheral blood samples of HNSCC patients collected after 
radiotherapy, the frequency of Treg cells was almost two times higher than in healthy subjects; 
moreover, CTLA4-expressing CD4 cells and PD-1 expressing T effector  cells were significantly 
higher in patients before treatment than in controls. In this paper was also observed that the 
fraction of proliferating CD4+ Treg cells increased after RT and that the levels of CTLA4+ and 














The purpose of this study was the immunological monitoring through multicolor flow 
cytometry of circulating T cells in HNSCC patients, analyzed before and after chemo-
radiotherapy treatment, in order to define the quality and intensity of the peripheral 
immunological response. 
Hence, multiparametric flow cytometry panels were structured to delineate : 
• CD4+ and CD8+ T lymphocyte maturation stages;  
• the cytokine production, such as IFN-γ, IL-17, IL-10 and Granzime B  by CD4+ and CD8+ 
T lymphocytes; 
• the regulatory commitment in both CD4+ Treg and CD8+ Treg ; 














3. Materials and Methods 
 
3.1 Patients 
This was a descriptive observational clinical study. Peripheral blood samples were collected 
from 20 patients affected by HNSCC (Table 3) who were enrolled at the Day-Hospital 
Therapeutics of the Radiotherapeutic Oncology Operative Unit and Otorhinolaryngology Clinic 
of the IRCCS Policlinico San Martino Hospital. The 20 patients enrolled were monitored up to 
32 months (range from 18 to 32 months for alive patients) in order to determine their clinical 
outcome. 
The study was carried out in compliance with the Helsinki Declaration and approved by the 
Ethical Committee of the San Martino Hospital in Genoa (P.R.133REG2017). All enrolled 
patients provided written informed consent. 
 
3.2 Isolation of peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized peripheral blood 
by centrifugation on Ficoll-Hypaque density gradient (Biochrom AG). PBMCs were collected 
and washed twice with 1X PBS phosphate buffer saline and resuspended in RPMI 1640 
(Invitrogen) supplemented with 10% autologous plasma. The cells were counted in crystal 







3.3 Immunofluorescence analyses  
Immunofluorescence analyses were performed on 1x106 PMBCs in 100 μl of PBS incubating 
with specific fluorochrome-conjugated monoclonal antibodies (mAbs).  
The following mAbs specific for surface markers were used (Supplementary Table 2): Brilliant 
Violet(BV)605-conjugated anti-human CD45RA clone HI100 (BD Biosciences), phycoerythrin 
(PE) or cyanin (Cy) 7-conjugated anti-human CCR7 clone 3D12 ((BD Biosciences), 
phycoerythrin (PE)-conjugated or BV421-conjugated anti-human CD127 clone HIL-7R-M21 
(BD Biosciences), Peridinin Chlorophyll Protein Complex-cyanin 5.5 (PerCP-Cy5.5)-conjugated 
or PE-Cy5.5-conjugated anti-human CD28 clone CD28.2 (BD Biosciences), fluorescein 
isothiocyanate (FITC)-conjugated anti-human CD25 clone M-A251 (BD Biosciences), BV711-
conjugated anti-CD39 clone TU66 (BD Biosciences), BV650-conjugated anti-human TIM-3 
clone 7D3 (BD Biosciences), BV786-conjugated anti-human PD-1 clone MIH4 (BD Biosciences), 
allophycocyanin (APC)-conjugated anti-human CD152 (CTLA-4) clone BNI3 (BD Biosciences), 
APC-H7-conjugated anti-human CD4 clone RPA-T4 (BD Biosciences), BV 421-conjugated or or 
Alexa Fluor 647-conjugated or PerCP-Cy5.5-conjugated anti-human CD8 clone RPA-T8 (BD 
Biosciences), BV450-conjugated or Alexa Fluor 700-conjugated anti-human CD3 clone UCHT1 
(BD Biosciences). To exclude dead cells, the samples were incubated with Aqua dead (Molecular 
Probes, Thermo Fisher) for 15 min at room temperature, before proceeding with surface 
staining. Cells were washed with PBS-BSA 0.01% and incubated with the surface mAbs.  
After surface staining, the cells were fixed and permeabilized by Transcription Buffer Set (BD 
Pharmingen) prior to perform intranuclear  staining for 30 min in the dark with the following 
mAbs: PE-CF594-conjugated anti-human FoxP3 clone 259D/C7 (BD Biosciences). The cells 
were washed with 1 ml of PBS-BSA 0.01% and resuspended in 300 μl of PBS. The samples were 
acquired by a BD Fortessa X20 flow cytometer (BD Biosciences) using the BD FACS Diva™ 
software version 8.0 (BD Biosciences), and analyzed using FlowJo™ software v10.7. 
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3.4 Analysis of intracellular cytokines by flow cytometry  
The intracellular production of IFN-γ, IL-17A, IL-10 and GranzimeB by T lymphocytes from 
PBMC was analyzed as follows: the cells (resuspended in culture medium conditioned with 10% 
autologous plasma at a concentration of 1 x 107/ml) were stimulated with phorbol-12-
myristate-13-acetate (PMA 50 ng/ml, Sigma) and ionomycin (2 μg/ml, Sigma) for 5 hours at 
37°C. Brefeldin A (BFA 10 μg/ml, Sigma) was added to the cells for the last 4 hours of incubation. 
After washings, the samples were stained with fluorochrome-conjugated mAbs specific for 
surface markers [PerCPCy5.5 anti-CD3 (BD), APC-Cy7 anti-CD8 (e-Biosciences) and Violet 
Live/Dead Fixable Dead Cell stain (Life Technologies, CA, USA)], before fixing and 
permeabilizing the lymphocytes with the Cytofix/Cytoperm kit (BD Bioscience) following the 
manufacturer’s instructions. The cells were washed in Perm-Wash buffer (BD Bioscience) and 
incubated with Pe-Cy7 anti-IFNγ (BD), FITC anti- GranzimeB (BD), PE anti-IL17A (e-Bioscience) 
mAbs, PECF594 anti IL10 (BD). Thereafter, the samples were washed in Perm-Wash buffer, 
fixed with FACS Lysing solution (BD Bioscience) and stored at 4 °C. The cytokine profile was 
acquired by a BD Fortessa X20 flow cytometer (BD Biosciences) using the BD FACS Diva™ 
software version 8.0 (BD Biosciences), and analyzed using FlowJo™ software v10.7. 
 
3.5 Statistical analyses 
Results were reported with mean and standard deviation (SD). To compare the frequency of 
the different T cell subsets between the tumor infiltrates of the two groups, we used the 
independent samples Student’s t-test for not skewed populations or non-parametric Mann-
Whitney test for all other populations; two-sided tests were always applied.  
Analyses were performed by GraphPad Prism 5 for Mac OS X and Stata Statistical Software, 






To perform the project, circulating CD4+ and CD8+ T lymphocyte sub-populations, with effector 
or regulatory characteristics, were analyzed in 20 HNSCC patients before and after undergoing 
chemo-radiotherapy treatment.  
HNSCC patients have distinct characteristics, summarized in Table 1, in terms of: HPV infection 
(9 HPV negative tumors, 10 HPV-16-associated HNSCC),  smoking and tumor staging. 
Blood samples collection acquisition by flow cytometry was conducted prior to initiation of 
anticancer treatment, and after a period of 1 month from the interruption of the anticancer 
treatment. 
 
  Smoke HPV-16 Stage Therapy 
Subject 1 Yes Negative 4b2b RT+CHT 
Subject 2 Yes Negative 4a2b RT+CHT 
Subject 3 Yes Positive 4b2c RT+CHT 
Subject 4 Yes Positive 4N1 RT+CHT 
Subject 5 Yes Negative 42c RT+CHT 
Subject 6 Yes Negative 2n0 RT 
Subject 7 Yes Negative 1n2b RT+CHT 
Subject 8 Yes Positive 4n2c RT+CHT 
Subject 9 Yes Negative 4an2b RT+CHT 
Subject 10 Yes Positive 4n2c RT+CHT 
Subject 11 Yes Negative 2n2c RT+CHT 
Subject 12 No Positive 4n2c RT+CHT 
Subject 13 No Positive na Surgery 
Subject 14 yes Negative 4n3 RT-CHT 
Subject 15 No Positive 2n2b RT+CHT 
Subject 16 No Positive 2n0 RT 
Subject 17 Yes Positive 1n2c RT+CHT 
Subject 18 No Positive 2n1 RT 
Subject 19 Yes n.a. 4n2c RT+CHT 
Subject 20 Yes Negative 4an2c RT+CHT 
 





4.1 CD4+ and CD8+ T lymphocyte populations 
 
 
CD4+ and CD8+ T lymphocyte subpopulations have been analyzed by flow cytometry in 
Peripheral Blood Mononuclear Cells (PBMC) isolated from blood samples collected from 
patients before therapy (PRE) and after therapy (POST), and compared with PBMC derived 
from healthy controls (HC, n = 9), matched for age and sex. Fig 12 A shows the gating strategy 
that includes: 1) Discrimination of viable CD3 + cells (CD45 dot plot versus viability dye); 2) 
Discrimination of the lymphocyte population by light scatter characteristics (dot plot FSC-A 
versus SSC-A); 3) Electronic exclusion of Singlets doublets (FSC-A versus FSC-H dot plot); 4) 












Fig.12 T-cell subsets in PBMC of HNSCC  patients before and after therapy and PBMC of healthy controls. 
A. Dot plots show the gating strategy of multiparametric flow cytometry analysis utilized for the selection of the CD3+CD4+ 
and CD3+CD8+ T cell subpopulations. B.  Histograms show the percentage  of total CD3+ T cells of PBMC in healthy controls 
(HC), in PBMC collected from HNSCC patients  before (PRE) and after therapy (POST). C. and D. Histograms show the 
percentage  of CD4+ and CD8+ T cells of PBMC in healty controls (HC), of PBMC collected from HNSCC subjects before (PRE) 
and after therapy (POST), referred to CD3+ cells. Values are represented as Mean ± SD; Statistical significance was determined 
using paired or unpaired Student’s t-test: *p<0.05; **p<0.01; ***p<0.001. 
 
 
CD3+ T lymphocyte frequency of PBMC POST samples resulted significantly lower to those of 
both PBMC PRE samples (28.9 ± 12 % versus 38.3 ± 10 , p < 0.001) and control subjects (44.6 
± 9%, p<0.05). (Fig 12 B) 
The same behavior was observed regarding the frequency of circulating CD4+ T subset that 
significantly decreased after therapy (58 ± 16% versus 44 ± 15%; p < 0.0001), and resulted 
lower in POST samples compared to HC (65 ± 12%). (Fig 12 C) 
Whereas, CD8+ T cell population showed an increment in samples collected from treated 
patients: in fact, the data showed a significant difference between PBMC POST and both PBMC 




4.2 Non-regulatory CD4+ T cells: maturation and cytokine production 
 
To describe the maturation stages of CD4+T lymphocyte, CD45RA and CCR7 markers were 
used.  As shown in figure 13 Panel A, the use of these two markers allows to identify four 
different CD4+ lymphocytes maturation stages: NAIVE (CD45RA+CCR7+), Central Memory T 
cells (CM; CD45RA-CCR7+), Effector Memory (EM; CD45RA-CCR7-) and  Terminal Effector 
Memory (TEMRA; CD45RA+CCR7-). 
 
 
Fig.13 CD4+ T cells maturation  in PBMC of HNSCC  patients before and after therapy and PBMC of healthy controls. 
A. Dot plots show the maturation of CD3+CD4+ along the expression of CD45RA and CCR7 markers: T Naïve (CD45RA+CCR7+) 
Central memory T cells or CM (CD45RA-CCR7+) T Effector Memory or EM (CD45RA- CCR7-)Terminal Effector Memory or 
TEMRA (CD45RA+ CCR7-). B. C. D. and E. Histograms show the percentage  of CD3+CD4+ Naïve cells, CD3+CD4+ CM cells, 
CD3+CD4+ EM cells, CD3+CD4+ TEMRA cells respectively of PBMC in healty controls (HC), of PBMC collected from HNSCC 
subjects before (PRE) and after therapy (POST). Values are represented as Mean ± SD; Statistical significance was determined 




In the cohort of samples examined, CD4+ Naïve T cells constituted the 37± 13% of T cells in the 
peripheral blood of healthy controls, their percentage in PBMC PRE was 32.4 ± 13% and in 
PBMC POST was 16±15% (Fig 13 B). The percentage in samples collected after therapy was 
significantly decreased compared to PBMC PRE (p < 0.0001). 
CM CD4+ T cells (Fig 13 C) were significantly less present among PBMC HC population (16 ± 
9%) compared to CM subset in PBMC PRE (33 ± 9%; p < 0.005); CM CD4+ T population was 
significantly lower among PBMC POST (20 ± 9%; p < 0.005) compared with samples collected 
from patients HNSCC before therapy. 
CD4+ Effector Memory T cells in PBMC HC and in PBMC PRE were comparable (29.6 ± 16% vs. 
20 ± 9%). They significantly increased in PBMC POST compared to PBMC PRE (49 ± 9%; p < 
0.0001) and to PBMC HC (p<0.05). (Fig 13 D) 
Percentages of Terminal Effector memory CD4+ T cells in samples derived from patients at 
different time point and control donors were comparable  (PBMC HC 17± 8%;  PBMC PRE 14.4 
± 8%; PBMC POST 12.6 ± 14%). (Fig 13 E)  
To evaluate if the therapy could influence the effector capacities of CD4 + T cells in terms of 
cytokine release and cytotoxicity, the intracellular production of IFN-γ, IL1-7A, IL-10 and 
Granzime B by CD4+ T lymphocytes was taken into consideration before and after therapy. The 
data showed no significant difference in the production of IFN-γ, IL-17A or IL-10 cytokines 










Fig.14 Frequencies of CD4+ T effector cells. 
A. and B. Histograms show the percentage  of CD4+GranzimeB+ T lymphocytes in PBMC collected from HNSCC subjects before 
(PRE) and after therapy (POST). C. D. and E. Histograms show the percentage  CD4+CTLA-4+, CD4+PD1+ and CD4+CD39+ T 
lymphocytes respectively of PBMC in healthy controls (HC), of PBMC collected from HNSCC subjects before (PRE) and after 
therapy (POST). Values are represented as Mean ± SD; Statistical significance was determined using paired or unpaired 
Student’s t-test: *p<0.05; **p<0.01; ***p<0.001. 
 
Whereas the analyses showed a significant increment   of the percentage of  Granzime B+ CD4+T 
cells in  blood samples  collected after therapy  (PBMC PRE 2.5± 2.9% vs PBMC POST  4.2 ± 
4.9%; p < 0.05). (Fig 14 A)  
Moreover, we examined the impact of anticancer therapy on expression of Inhibitory receptors 
(iRs)/exhaustion markers, as CTLA-4, PD-1 and CD39,  on peripheral CD4+T cells.  
In general, the expression of CTLA-4, PD-1 and CD39 exhaustion markers resulted higher on 
CD4+T cells in samples derived before the therapy than in samples derived from healthy 
controls, as expected in a chronic immune stress situation.  
The data highlighted that the percentage of CTLA-4+ CD4+ T cells was significantly higher  in 
PBMC PRE compared to that in both PBMC HC (11.6 ± 11.5% vs 2.3 ± 5.1%, respectively; p < 
0.05) and  PBMC POST (1.4 ± 1.6%; p < 0.0001). (Figure 14 B) 
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The analyses of PD-1+CD4+ T cells showed increased frequency of these cells in PBMC POST 
(18.5 ± 10.4 %) with respect to that in both PBMC PRE (6.5 ± 9.9%, p < 0.001) and PBMC HC 
(4.3 ± 1.5%, p < 0.001). (Figure 14 C) 
Similar findings were observed concerning CD39 expression. In fact, the frequency of CD39+ 
CD4+ T-cell subset  was increased in the of PBMC POST (9.9 ± 5.1%) compared to those of both 
PBMC PRE  (18.0 ± 11.2%; p < 0.001) and PBMC HC (2.2 ± 1.8%) (Figure 14 D) 
 
4.3 CD4+ Treg 
Figure 15 A shows the gating strategy for the evaluation of the CD4+CD25high FOXP3+ Treg 
population;  the CD25high FOXP3+ population was defined on the CD3+CD4+ population (dot 
plot analyzing FoxP3 versus CD25) and the CD25high FOXP3+ gate was verified for negativity on 
the CD3+CD8+ population. 
In general, the frequency of CD4+CD25high FOXP3+ regulatory T cells resulted  higher in the 
peripheral blood of HNSCC subjects before and after therapy (PBMC PRE 2.02 ± 0.9%; PBMC 
POST 1.8 ± 1.5%;) compared to healthy controls (PBMC HC 0.7 ± 0.28%) even without reaching 
statistical significance. (Figure 15 B) 
Attention was also posed on a functional characterization of CD4+ Treg.  
Based on what is proposed by the model described by Sakaguchi, we can distinguish three 
subpopulations, equipped or not with suppressive activity, using the modulation of  
FoxP3/CD25 and CD45RA markers :  
(i) Naïve or resting Treg cells (CD45RA+FoxP3 low /CD25low) with low suppressive activity; (ii) 
effector or activated Treg cells (CD45RA–FoxP3high/CD25high) with strong suppressive function; 
(iii ) non-Treg cells (CD45RA– FoxP3 low/CD25low) without  suppressive ability . 
The frequency of Naïve Treg was higher among PBMC HC (13.6 ± 5.4%) compared to PBMC PRE 
(7.9 ± 5.2%) and PBMC POST (4.5 ± 4.1%) even without reaching statistical significance; 
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however, in patients Naïve Treg frequency was significantly decreased in PBMC POST with 
respect to PBMC PRE value (p < 0.05). (Figure 15 C)  
Non-Treg CD45RA– FoxP3 low/CD25low CD4+ T cells were more represented in PBMC PRE (31 
± 14.2%) than in both PBMC HC (18.5 ± 5.6%, difference not fully significant) and PBMC POST 
(15.3 ± 6.2 %; p < 0.0001). (Figure 15 D) 
Consistent with the possible effect of the therapy, activated CD4+Treg significantly increased 
in post-therapy compared to pre-therapy samples (PBMC PRE 14± 7.3% vs PBMC POST 23.6 ± 
8.5%; p < 0.0001). (Figure 15 E) 
No significant differences among groups were observed concerning the frequencies of PD-1+ 
CD4+ Treg (Figure 15 F).  
Instead the frequency of CD39+ Treg  was significantly increased in PBMC POST (58.3 ± 23%) 
with respect to both PBMC PRE (47.8 ± 24%, p<0.05) and PBMC HC (20.4 ± 27%, p<0.05). 







Fig. 15 CD4+ Treg cell subsets in PBMC of HNSCC  patients before and after therapy and PBMC of healthy controls. 
A. Dot plot representation shows the gating strategy of multiparametric flow cytometry analysis utilized for the selection of 
the CD4+ Treg cells population. B.  Histograms show the percentage  of CD4+ Treg cells of PBMC in healthy controls (HC), of 
PBMC collected from HNSCC subjects before (PRE) and after therapy (POST), referred to CD3+ T cells C. D. and E. Histograms 
show the percentage  of Naïve or resting Treg cell (CD45RA+FoxP3low/CD25low), non-Treg cells (CD45RA– FoxP3low/CD25low) 
and effector or activated Treg cells (CD45RA– FoxP3low/CD25high) respectively of PBMC in healthy controls (HC), of PBMC 
collected from HNSCC subjects before (PRE) and after therapy (POST), referred to CD3+ T cells. F. and G Histograms show the 
percentage  CD4+ PD1+Treg and CD4+ CD39+Treg  T lymphocytes respectively of PBMC in healthy controls (HC), of PBMC 
collected from HNSCC patients before (PRE) and after therapy (POST). Values are represented as Mean ± SD; Statistical 





4.4 Non-Treg CD8+ T cells: maturation and cytokine production 
 
To describe the dynamic of CD8+T cells induced by anticancer therapy, the analysis of 
maturation stages was performed in peripheral CD8+ T lymphocytes, evaluating the 
expression of CD45RA and CCR7 markers to  identify: NAIVE  cells (CD45RA+CCR7+), Central 
Memory cells (CM; CD45RA-CCR7+), Effector Memory cells (EM; CD45RA-CCR7-) and  
Terminal Effector Memory cells (TEMRA; CD45RA+CCR7-), as shown in Figure 16, before 
and after anticancer therapy (Panel A) in peripheral blood derived from HNSCC patients and 
healthy controls. 
A decreased frequency of Naïve CD8+ T cells was observed in PBMC POST (6.3 ± 9.4%) with 
respect to PBMC PRE (13.3 ± 13.7%, p < 0.05) and to PBMC HC (17.6± 8.7%, not significant). 
(Fig 16 B)  
Concerning CM CD8+ T cell frequency, it was lower in  less in  PBMC POST  (2 ± 1.4 %) than 
in PBMC PRE (3.4 ± 2.8%, p < 0.001) and  PBMC HC (5.3 ± 2.8%, not significant) (Fig 16 C) 
The frequencies of EM CD8+ T cells in PBMC PRE were significantly higher than in both PBMC 
POST (37.7 ± 30% vs. 18 ± 9.9%; p < 0.001) and PBMC HC (14.8 ± 12.9%, not significant). 
(Fig 16 D) 
Finally, the frequency of TEM CD8+ T cells in PBMC PRE (44 ± 25.2%) resulted  significantly 
lower than in PBMC POST (72.3 ± 13%, p < 0.001) and comparable to that of PBMC HC (63.8± 







Fig.16 CD8+ T cells maturation  in PBMC of HNSCC  patients before and after therapy and PBMC of healthy controls. 
A. Dot plot representation show the maturation of CD3+CD8+ along the expression of CD45RA and CCR7 markers: T Naïve 
(CD45RA+CCR7+) Central memory T cells or CM (CD45RA-CCR7+) T Effector Memory or EM (CD45RA- CCR7-)Terminal 
Effector Memory or TEMRA (CD45RA+ CCR7-). B. C. D. and E. Histograms show the percentage  of CD3+CD8+ Naïve cells, 
CD3+CD8+ CM cells, CD3+CD8+ EM cells, CD3+CD8+ TEMRA cells respectively of PBMC in healthy controls (HC), of PBMC 
collected from HNSCC subjects before (PRE) and after therapy (POST). Values are represented as Mean ± SD; Statistical 





As for the CD4+ T cells, non-Treg CD8+T cells were also evaluated before and after anticancer 
therapy for: (i) intracellular production of IFN-γ, IL-17A, IL-10 cytokines and Granzime B by 
CD8+ T lymphocytes; (ii) expression of co-stimulatory (CD28) and co-inhibitory molecules 
(CTLA-4, PD-1 and CD39). 
Concerning both cytokine profile and Granzyme production by non-Treg CD8+T cells, no 
significant differences in production of any analyzed cytokine (IL-17A, IL-10 and IFNγ+) 
were found among the different groups (data not shown). 
Interestingly, the frequency of CD8+CD28- T cells resulted  significantly higher in PBMC PRE 
if compared with samples collected from healthy subjects (PBMC HC) (50.3 ± 29.8% vs 24.2 
± 7.2%; p < 0.05) and further increased in PBMC POST (63.5 ± 22.8%; p < 0.05).  (Fig 17 C) 
Regarding the assessment of the state of exhaustion, the expression of Inhibitory receptors 
(iRs), as CTLA-4, PD-1 and CD39 was also examined on CD8+T cells.  
The data showed: 
i) comparable frequencies of both CTLA-4+CD8+ and CD39+CD8+ T cell subsets among the 
groups (Fig 16 D and Fig 17 F); 
ii) significantly increased frequencies of PD-1+CD8+ T cells in PBMC POST with respect to 





Fig.17 Frequencies of CD8+ T cells effector. 
A. Histograms show the percentage CD8+CD28-+ lymphocytes respectively of PBMC in healthy controls (HC), of PBMC 
collected from HNSCC subjects before (PRE) and after therapy (POST). B. Histograms show the percentage  of CD8+IFNγ+ 
and CD8+IL17+ T lymphocytes in PBMC collected from HNSCC subjects before (PRE) and after therapy (POST). D. E. and F. 
Histograms show the percentage CD8+CTLA-4+, CD8+PD1+ and CD8+CD39+ T lymphocytes respectively of PBMC in 
healthy controls (HC), of PBMC collected from HNSCC subjects before (PRE) and after therapy (POST). Values are 













4.5 CD8+ Treg 
Figure 18 A shows the gating strategy for the analysis of the CD8+ Treg population. Briefly, 
the CD8+ CD28- population (dot plot showing CD8 versus CD28) was initially defined by 
verifying the negativity threshold of the CD28 marker on the CD3+CD4+ T population (dot 
plot showing CD4 versus CD28). Then, the subset of CD127-CD39+ T cells (dot plot showing 
CD127 versus CD39) was identified on the CD8+CD28- T cell population, , thus defining the  
CD8+CD28-CD127-CD39+ T regulatory subset.  
To fully analyze the arm of the regulatory T cells, the frequencies of CD8+CD28-CD127-
CD39+ T regulatory lymphocytes were evaluated in healthy donors and in samples of HNSCC 
patients before and after anticancer therapy: no significant differences were detected among 









Fig.18 CD8+ Treg cell subsets in PBMC of HNSCC  patients before and after therapy and PBMC of healthy controls. 
A. Dot plots show the gating strategy of multiparametric flow cytometry analysis utilized for the selection of the CD8+ Treg 
cells population. B.  Histograms show the percentage  of CD8+ Treg cells of PBMC in healty controls (HC), of PBMC collected 
from HNSCC subjects before (PRE) and after therapy (POST), referred to CD3+ cells C. Histograms show the percentage  
CD8+ Treg PD1+ lymphocytes respectively of PBMC in healty controls (HC), of PBMC collected from HNSCC subjects before 












HNSCC is a relevant medical issue since it is the sixth most common cancer globally and 
represent about 3% of all malignant tumors in Italy. The malignant tumors of the head and 
neck are almost represented by squamous cell carcinomas with an extremely variable 
biological behavior. 
HNSCC is generally associated with a history of alcohol and tobacco consumption or abuse, 
and an etiopathogenetic factor is HPV infection.  
Surgery, radiotherapy and chemotherapy in various combinations are used in the treatment 
of head and neck cancers, depending on the TNM stage. Radiotherapy associated with 
cisplatin-based chemotherapy is considered the standard, as chemo-radiotherapy compared 
to radiotherapy alone has shown a significant improvement in overall survival. 
Frequent data in the literature are focused on monitoring the immune response of patients 
undergoing chemotherapy, radiotherapy or immunotherapy treatments. Very few studies, 
especially on head and neck tumors, assessed so far the characteristics of the peripheral 
immune response in reference to the chemoradiotherapy treatment.  
Balázs K. and collegues [60] reported that in peripheral blood samples of HNSCC patients 
collected after radiotherapy the fraction of Treg cells was almost two times higher than 
healthy controls, and CTLA4-expressing CD4 cells and PD-1 expressing T effector cells were 
significantly higher in patients before treatment with respect to healthy controls. They also 
observed that the fraction of proliferating CD4+ Treg cells increased after RT and that the 
levels of CTLA4+ and PD-1+ increased on CD4+ T effector  cells. 
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Exposure of tissue to ionizing radiation and chemo agents has different effects from 
inflammation to distinct forms of programmed cell death. It is known that the success of 
concurrent chemo-radiation treatment relies in the achievement of immunogenic cell death 
and in the consequent release of  tumor neoantigens in an immunogenic way. On the other 
hand, is well known the adverse influence of chemo/radiotherapy on affecting leukocyte’s 
production by the bone marrow, that could lead to abnormal hematopoiesis, in addition to a 
significant reduction in the number of the leukocytes that could persist also 4 weeks after 
treatment.  
Immunogenic cell death (ICD) and priming of antitumor T-cell responses are closely related, 
in fact ICD is an efficient process to transfer antigens from tumor cells to DCs and that DCs 
are required to activate tumor-specific T cells.  Different signals are required to achieve an 
ICD , they include: 1) cell surface translocation of calreticulin (an endoplasmic reticulum 
resident protein); 2) extracellular release of high-mobility group protein B1 (HMGB1, a 
nonhistone nuclear protein), and 3) release of ATP (the primary unit of cellular energy 
transfer). These molecular signals are correlated to the instauration of a proinflammatory 
milieu, with the release of: 1) chemokines CXCL9, CXCL10, and CXCL16, which promote 
recruitment of effector CD8 and T-helper 1 CD4 T cells; 2) and proinflammatory cytokines 
induced by radiation including interleukin 1β, tumor necrosis factor α and type 1 and 2 
interferons. In addition, tumor cells undergo phenotypic changes that enhance their 
susceptibility to immune effectors, enhancing the expression of death receptors, MHC class 
1 molecules, costimulatory molecules, adhesion molecules, and stress-induced ligands, 
increasing their recognition and killing by T cells. 
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Chemo-radiotherapy treatment engages both the innate and adaptive arms of the immune 
system, by coupling release and/or expression of new antigens with immune adjuvant-like 
effects, and acts as a vaccine that elicits tumor-specific T cells. Once vaccinated, the host is 
endowed with immune memory, a powerful weapon active against synchronous non-
irradiated tumor sites (abscopal effects) and potentially against cancer cells that emerge 
from dormancy during the life of the host. 
In the study presented here,  peripheral blood of 20 patients suffering for HNSCC were 
examined in order to define the qualitative and quantitative characteristics of their 
immunological T cell response, before and after these subjects underwent chemo-
radiotherapy treatment using multiparametric flow cytometry. 
In the cohort of patients here examined, it is evident a decrease of the CD3+ total T cell 
compartment after therapy. Concerning the CD4+ T cells, therapy mainly induced a switch 
from the naïve to the EM cell subset, associated with an increase in Granzyme secreting CD4+ 
T cells. These findings suggest that the treatment induced functional maturation of CD4+ T 
lymphocytes producing cells prone to exert effector functions. This is corroborated by the 
decrease of the CD4+ T cells expressing CTLA-4, that is an IR mainly expressed during early 
maturation stages, and by the increased frequency of CD4+ T cells expressing the PD-1 
molecule, typical of late maturation stages, phenotypic changes shared by both non-Treg and 
Treg CD4+ T cell subsets. 
Interestingly, the analysis of the CD8+ T cell compartment provided data supporting the 
concept that therapy may induce pro-maturation effects on T cells pushing them toward 
acquisition of full effector functions. Indeed, this is suggested by the expansion of the 
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CD8+CD28- T cell subset and by the decrease of the early maturation stages associated with 
the increase of TEM CD8+ T cells, a subset of effector T lymphocytes prone to migrate into 
tissues. Moreover, no signs of CD8+ Treg expansion were observed.  
All together these data have relevance since apparently overturn the common view assessing 
for a hampering effect of ablative therapy on the immune system, instead suggesting its 
activatory effect on the immune system. This may find an explanation thinking at the huge 
amount of cell death products acting as danger signals raised by chemotherapy-Rt 
combination and by the subsequent stimulation of cancer specific immune responses 
induced by antigen spreading. The fact that both effector CD4+ and CD8+ T cell subsets, 
expanded after therapy, uploaded PD-1 is also noteworthy since supports the likely utility of 
a combined use of PD-1 blockers with chemo-Rt therapy. 
In conclusion, our data show that in HNSCC patients current therapeutic approaches, based 
on administration of chemotherapy and/or radiotherapy, induce activation of the immune 
system leading to maturation of effector T cell subpopulations. Subsequent investigations on 
the leukocyte formula will prove useful and correlated with the more well-known effects of 
chemo-Rt therapy. Moreover they are in support of the inclusion of PD-1 inhibiting agents to 
the therapeutic armamentarium against HNSCC in order to prevent T cell exhaustion and to 
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